{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:13:09Z","timestamp":1783944789193,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102569","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:14:41Z","timestamp":1777590881000},"page":"102569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-0915","authenticated-orcid":false,"given":"Colin P.","family":"Bergstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-9775","authenticated-orcid":false,"given":"Cameron","family":"Chalker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8951-0677","authenticated-orcid":false,"given":"Joseph","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcak","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-4426","authenticated-orcid":false,"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2026.102569_bib0001","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0002","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2026.102569_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102569_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/15384047.2022.2037985","article-title":"Lutetium-177-PSMA-617: A Vision of the Future","volume":"23","author":"Chandran","year":"2022","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.1016\/j.clgc.2026.102569_bib0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102569_bib0008","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clgc.2026.102569_bib0009","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/RLU.0000000000002561","article-title":"First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands","volume":"44","author":"van Kalmthout","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.clgc.2026.102569_bib0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","article-title":"Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis","volume":"43","author":"Kim","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"10459","key":"10.1016\/j.clgc.2026.102569_bib0011","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12894-022-01050-3","article-title":"Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy","volume":"22","author":"Wrenger","year":"2022","journal-title":"BMC Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102569_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270956","article-title":"Bone marrow involvement in patients with metastatic castration sensitive prostate cancer","volume":"17","author":"Shahait","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2026.102569_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"47","key":"10.1016\/j.clgc.2026.102569_bib0015","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035843","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617","volume":"102","author":"\u015eahin","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102260","article-title":"Safety and Efficacy of 177Lu-PSMA Therapy Following 223Radium Treatment: A Retrospective Multinational Real-World Analysis","volume":"23","author":"Giannini","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0017","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12894-022-01050-3","article-title":"Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy","volume":"22","author":"Wrenger","year":"2022","journal-title":"BMC Urol"},{"issue":"14","key":"10.1016\/j.clgc.2026.102569_bib0018","first-page":"1351","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy","volume":"83","author":"Stangl-Kremser","year":"2023","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1102\/1470-7330.2009.0005","article-title":"Biopsy of renal masses: when and why","volume":"9","author":"Sahni","year":"2009","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.clgc.2026.102569_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-015-1599-9","article-title":"Neutrophil count is associated with survival in localized prostate cancer","volume":"15","author":"Bahig","year":"2015","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2026.102569_bib0021","first-page":"581","article-title":"Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database","volume":"29","author":"Vidal","year":"2018","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2015.07.018","article-title":"Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer","volume":"14","author":"Kwon","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102569_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100241","article-title":"Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study","volume":"6","author":"de Wit","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.clgc.2026.102569_bib0024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000541881","article-title":"The Immune Microenvironment in Prostate Cancer: A Comprehensive Review","volume":"103","author":"Novysedlak","year":"2025","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.clgc.2026.102569_bib0025","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMoa2511882","article-title":"Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia","volume":"394","author":"Al-Samkari","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102569_bib0026","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-10-284","article-title":"Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases","volume":"10","author":"Nieder","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0027","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.clgc.2026.102569_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102862","article-title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","volume":"77","author":"Herrmann","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.clgc.2026.102569_bib0029","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41598-023-29634-5","article-title":"Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients","volume":"13","author":"Hakozaki","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clgc.2026.102569_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3892\/ol.2022.13425","article-title":"Role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer","volume":"24","author":"Huszno","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clgc.2026.102569_bib0031","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12935-019-0785-2","article-title":"Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis","volume":"19","author":"Peng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clgc.2026.102569_bib0032","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-015-1599-9","article-title":"Neutrophil count is associated with survival in localized prostate cancer","volume":"15","author":"Bahig","year":"2015","journal-title":"BMC Cancer"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102569_bib0033","doi-asserted-by":"crossref","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8051","key":"10.1016\/j.clgc.2026.102569_bib0034","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-024-08378-w","article-title":"A vision-language foundation model for precision oncology","volume":"638","author":"Xiang","year":"2025","journal-title":"Nature"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:52:14Z","timestamp":1783943534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000698"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102569","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102569"}}